Paper Details

  1. Home
  2. Paper Details

Lenvatinib: Role in thyroid cancer and other solid tumors.

Author: CabanillasMaria E, HabraMouhammed Amir

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article discusses the use of lenvatinib, a small-molecule tyrosine kinase inhibitor, for the treatment of advanced thyroid cancer. It highlights the drug's mechanisms of action, clinical trial results, and adverse events.
Paper Details　
Original Abstract of the Article :
Despite recent breakthroughs in treatment of advanced thyroid cancers, prognoses remain poor. Treatment of advanced, progressive disease remains challenging, with limited treatment options. Small-molecule tyrosine kinase inhibitors, including vandetanib, cabozantinib, sorafenib, and lenvatinib, whic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ctrv.2015.11.003

データ提供：米国国立医学図書館（NLM）

Lenvatinib: A New Hope for Thyroid Cancer

Thyroid cancer, like a stubborn desert cactus, can be difficult to eradicate. This study investigates the potential of lenvatinib, a tyrosine kinase inhibitor, as a new treatment option for advanced thyroid cancer. The authors review the current understanding of lenvatinib's role in treating thyroid cancer and other solid tumors, based on clinical trial data.

Lenvatinib Demonstrates Promising Antitumor Activity

The study highlights the promising antitumor activity of lenvatinib in advanced thyroid cancer. Lenvatinib has shown significant clinical benefit in patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) and has also been investigated in phase II trials for medullary thyroid cancer (MTC). Its antitumor activity is attributed to its ability to inhibit the growth of blood vessels that supply tumors and to directly kill cancer cells.

Implications for Thyroid Cancer Treatment and Research

This review underscores the potential of lenvatinib as a new and effective treatment option for advanced thyroid cancer. The drug's demonstrated clinical benefit and favorable safety profile make it a promising addition to the therapeutic armamentarium for this challenging disease. Continued research is needed to further explore the efficacy and optimal use of lenvatinib in treating thyroid cancer and other solid tumors.

Dr. Camel's Conclusion

This review is a beacon of hope in the fight against thyroid cancer. Lenvatinib offers a new and potentially life-extending treatment option for individuals facing this challenging disease. As scientists continue to explore the complexities of cancer and develop novel therapies, we may one day see a world where cancer is no longer a formidable foe but a manageable condition. The journey to conquering cancer may be long and winding, but research like this offers valuable insights and promising new avenues for treatment.

Date :
  1. Date Completed 2016-05-02
  2. Date Revised 2017-09-30
Further Info :

Pubmed ID

26678514

DOI: Digital Object Identifier

10.1016/j.ctrv.2015.11.003

Related Literature

Article Analysis
・Effects of cabozantinib (thyroid cancer)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.